Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris
- PMID: 32201461
- PMCID: PMC7062819
- DOI: 10.6515/ACS.202003_36(2).20190731A
Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris
Abstract
Background: Endothelial cell-specific molecule 1 (ESM-1 or endocan) is an immunoinflammatory marker strongly associated with inflammation, vascular endothelial dysfunction and atherosclerosis. We explored the relationship between serum endocan concentrations and coronary in-stent restenosis (ISR).
Methods: Fifty consecutive patients with ISR and 50 control subjects were included in this study. Clinical data and angiographic characteristics were collected. Serum endocan concentrations were measured using an enzyme-linked immunosorbent assay.
Results: All included patients were divided into four quartiles based on their concentrations of endocan: quartile 1 (0.62-1.31 ng/mL), quartile 2 (1.33-1.74 ng/mL), quartile 3 (1.75-2.77 ng/mL) and quartile 4 (2.78-4.24 ng/mL). The rates of ISR were 16%, 24%, 68%, and 92%, respectively. The patients in quartile 4 had significantly higher rates of ISR than the other groups (p < 0.001). Logistic regression analysis indicated that endocan concentration [odds ratio = 8.65, 95% confidence interval 3.56-20.94; p < 0.001] was an independent predictor of ISR. Receiver operating characteristic curve analysis was used to explore the relationship between endocan and ISR. Using a cutoff value of 1.625 ng/mL, endocan predicted ISR with a sensitivity of 86% and a specificity of 78%.
Conclusions: Our findings suggest that plasma endocan levels may be a novel biomarker of endothelial dysfunction in patients with ISR.
Keywords: Biomarker; Endocan; Endothelial cell-specific molecule 1; Inflammation.
Figures
Similar articles
-
The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis.Clin Chim Acta. 2015 Jun 15;446:248-52. doi: 10.1016/j.cca.2015.04.038. Epub 2015 May 8. Clin Chim Acta. 2015. PMID: 25958848
-
The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.Clin Chim Acta. 2018 Apr;479:20-24. doi: 10.1016/j.cca.2018.01.004. Epub 2018 Jan 3. Clin Chim Acta. 2018. PMID: 29305846
-
Serum endocan levels as a marker of disease activity in patients with Behçet disease.J Am Acad Dermatol. 2014 Feb;70(2):291-6. doi: 10.1016/j.jaad.2013.09.013. Epub 2013 Oct 28. J Am Acad Dermatol. 2014. PMID: 24176522
-
Endocan: A novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015 Nov;243(1):339-43. doi: 10.1016/j.atherosclerosis.2015.09.030. Epub 2015 Sep 26. Atherosclerosis. 2015. PMID: 26448266 Review.
-
Endocan: A Key Player of Cardiovascular Disease.Front Cardiovasc Med. 2022 Jan 5;8:798699. doi: 10.3389/fcvm.2021.798699. eCollection 2021. Front Cardiovasc Med. 2022. PMID: 35071362 Free PMC article. Review.
Cited by
-
The association of catestatin and endocan with the effects of cardiac shock wave therapy: Biomarker sub-study of the randomized, sham procedure-controlled trial.Front Cardiovasc Med. 2023 Feb 23;10:1004574. doi: 10.3389/fcvm.2023.1004574. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36910537 Free PMC article.
-
The Relationship Between Endocan and Serum Inflammatory Markers in Patients with Senile Calcific Aortic Stenosis.Anatol J Cardiol. 2024 Jan 7;28(2):102-8. doi: 10.14744/AnatolJCardiol.2023.3695. Online ahead of print. Anatol J Cardiol. 2024. PMID: 38168010 Free PMC article.
References
-
- Patel MJ, Patel SS, Patel NS, Patel NM. Current status and future prospects of drug eluting stents for restenosis. Acta Pharma. 2012;62:473–476. - PubMed
-
- Paudel B, Xuan GJ, Chun ZF. Analysis of clinical factors affecting the restenosis following percutaneous coronary intervention. Nepal Med Coll J. 2005;7:101–106. - PubMed
LinkOut - more resources
Full Text Sources